Please wait a minute...
浙江大学学报（医学版）
浙江大学学报（医学版）  2016, Vol. 45 Issue (4): 371-378    DOI: 10.3785/j.issn.1008-9292.2016.07.07
癌分子医学专题     
意义未明单克隆免疫球蛋白病及多发性骨髓瘤患者微RNA-221和微RNA-222的表达
杨肃文1, 王伟2, 金红1, 钟玉虹1, 谢鑫友1
1. 浙江大学医学院附属邵逸夫医院检验科, 浙江 杭州 310016;
2. 浙江省立同德医院检验科, 浙江 杭州 310012
Expression of microRNA-221/222 in patients with monoclonal gammopathy of undetermined significance and multiple myeloma
YANG Suwen1, WANG Wei2, JIN Hong1, ZHONG Yuhong1, XIE Xinyou1
1. Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China;
2. Clinical Laboratory, Tongde Hospital of Zhejiang Province, Hangzhou 310012, China
全文: PDF(1076 KB)  
摘要: 

目的：探讨意义未明单克隆免疫球蛋白病（MGUS）、多发性骨髓瘤（MM）患者血清和浆细胞中微RNA-221（miR-221）和微RNA-222（miR-222）的表达水平及其作为MGUS、MM诊断和预测预后生物学指标的可能性。方法：收集2013年1月至2015年12月浙江大学医学院附属邵逸夫医院及浙江省立同德医院14例初诊MGUS患者、81例初诊及复发MM患者和10名健康对照者的血清及骨髓标本，其中骨髓标本用CD138磁珠分选浆细胞。用实时定量PCR检测血清和浆细胞中miR-221/222的表达量。采用Δct表示miR-221/222的相对表达量并比较组间差异。比较缓解组和难治组MM患者治疗前后血清miR-221表达水平的变化，并分析其与血清β2微球蛋白的相关性。结果：MGUS患者和MM患者血清miR-221/222的表达量均较对照组高（均P<0.01），而浆细胞miR-221/222的表达量均较对照组低（P<0.05或<0.01）；MGUS与MM患者miR-221和miR-222表达量的差异在血清中或在浆细胞中均无统计学意义（均P>0.05）。miR-221和miR-222表达量在血清与浆细胞之间无相关性（r=0.024和-0.127，均P>0.05）；而血清和浆细胞miR-221与miR-222表达量之间均具有相关性（r=0.534和0.552，均P<0.01）。受试者工作特征（ROC）曲线显示血清miR-221/222和浆细胞miR-221/222诊断MGUS、MM的曲线下面积（AUC）分别为0.968和0.976、0.801和0.727。MM患者不同M-蛋白类型之间血清miR-221的表达量差异无统计学意义（P>0.05）。复发患者血清miR-221的表达量高于初诊患者（P<0.01）。DS分期为Ⅲ期MM患者血清miR-221表达量高于MGUS及DS分期Ⅰ期和Ⅱ期MM患者（P<0.01）。缓解组治疗后血清miR-221表达量低于治疗前（U=51.5，P<0.01），而难治组治疗前后血清miR-221表达量差异无统计学意义（U=67.5，P>0.05）。MM患者血清β2微球蛋白水平与血清miR-221的表达量呈正相关（r=0.524，P<0.01）。结论：检测患者血清、浆细胞miR-221/222表达量有助于MGUS的早期诊断，也有助于MM的诊断及疗效观察。
关键词 ： 多发性骨髓瘤/诊断,  多发性骨髓瘤/病理学,  单克隆丙种球蛋白病,良性/诊断,  微RNAs/血液,  预后    
Abstract：

Objective: To detect the expression of miR-221/222 in serum and plasma cells in patients with monoclonal gammopathy of undetermined significance(MGUS) and multiple myeloma(MM), and to explore the possibility of miR-221/222 as biomarkers in the diagnosis and prognosis predicting of MGUS and MM. Methods: Bone marrow and serum samples from 14 patients with newly diagnosed MGUS, 81 patients with newly diagnosed or relapsed MM and 10 controls were collected from Sir Run Run Shaw Hospital of Zhejiang University and Tongde Hospital of Zhejiang Province during January 2013 and December 2015. The expressions of miR-221/222 in serum and in sorted CD138 positive plasma cells were detected by qRT-PCR, and the relative expression of miR-221/222 (Δct) was compared between the groups. Serum levels of miR-221 before and after treatment were compared in both remission group (n=22) and refractory group (n=13) in MM patients, and its correlation with serum level of β2-MG was assessed using Pearson's correlation analysis. Results: Serum levels of miR-221/222 in MGUS and MM groups were significantly higher than those in control group (all P<0.01), while miR-221/222 levels in plasma cells were significantly lower in MGUS and MM groups than those in the control group (P<0.05 or<0.01). No significant difference in miR-221/222 levels in serum and plasma cells was observed between MGUS group and MM group (all P>0.05). There was no correlation between miR-221/222 levels in serum and plasma cells (r=0.024 and -0.127, all P>0.05), but miR-221 levels were correlated with miR-222 levels in both serum and plasma cells (r=0.534 and 0.552, all P<0.01). Receiver operating characteristic (ROC) curves showed that the areas under the curve (AUCs) of serum miR-221/222, plasma cell miR-221/222 in diagnosis of MGUS/MM were 0.968, 0.976, 0.801 and 0.727, respectively. There was no significant difference in serum level of miR-221 among MM patients with different paraprotein isotypes (P>0.05), but serum level of miR-221 in patients with relapsed MM was higher than that in patients with newly diagnosed MM (P<0.01). Compared with the patients with MGUS or MM stageⅠ and Ⅱ, patients with MM stage Ⅲ were of higher serum levels of miR-221 (P<0.01). Serum level of miR-221 decreased after chemotherapy in the remission group (U=51.5, P<0.01), but such decrease was not observed in the refractory group (U=67.5, P>0.05). Serum level of β2-MG was positively correlated with serum level of miR-221 (r=0.524, P<0.01). Conclusion: miR-221/222 in serum and plasma cells may be biomarkers for early diagnosis of MGUS, and are helpful for diagnosis and efficacy evaluation of MM.
Key words： Multiple myeloma/diagnosis    Multiple myeloma/pathology    Monoclonal gammopathies, benign/diagnosis    MicroRNAs/blood    Prognosis
收稿日期: 2015-12-31
CLC:  R733.3  
基金资助:

浙江省卫生科技计划（2013RCA034）；浙江省科技厅公益类项目（2013C33199）
通讯作者: 王伟(1968-),男,硕士,主任技师,主要从事免疫学检验及分子生物学研究;E-mail:wangweihz8@163.com;http://orcid.org/0000-0002-8511-1775     E-mail: wangweihz8@163.com
作者简介: 杨肃文(1975-),女,硕士,副主任技师,主要从事检验诊断学研究;E-mail:ysw13588708160@163.com;http://orcid.org/0000-0002-6295-5545
服务　　
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章　　

引用本文:

杨肃文 等. 意义未明单克隆免疫球蛋白病及多发性骨髓瘤患者微RNA-221和微RNA-222的表达[J]. 浙江大学学报（医学版）, 2016, 45(4): 371-378.
YANG Suwen, WANG Wei, JIN Hong, ZHONG Yuhong, XIE Xinyou. Expression of microRNA-221/222 in patients with monoclonal gammopathy of undetermined significance and multiple myeloma. Journal of ZheJiang University(Medical Science), 2016, 45(4): 371-378.

链接本文:

http://www.zjujournals.com/xueshu/med/CN/10.3785/j.issn.1008-9292.2016.07.07      或      http://www.zjujournals.com/xueshu/med/CN/Y2016/V45/I4/371

[1] OLTEANU H, WANG H Y, CHEN W, et al. Immunophenotypic studies of monoclonal gammopathy of undetermined significance[J/OL].BMC Clin Pathol, 2008, 8(1):13.
[2] JIKUZONO T, KAWAMOTO M, YOSHITAKE H, et al. The miR-221/222 cluster, miR-10b and miR-92a are highly upregulated in metastatic minimally invasive follicular thyroid carcinoma[J]. Int J Oncol, 2013, 42(6): 1858-1868.
[3] HWANG M S, YU N, STINSON S Y, et al. miR-221/222 targets adiponectin receptor 1 to promote the epithelial-to-mesenchymal transition in breast cancer[J/OL]. PLoS One, 2013, 8(6): e66502.
[4] PINEAU P, VOLINIA S, MCJUNKIN K, et al. miR-221 overexpression contributes to liver tumorigenesis[J]. Proc Natl Acad Sci U S A, 2010, 107(1): 264-269.
[5] LIU S, SUN X, WANG M, et al. A microRNA 221- and 222-mediated feedback loop maintains constitutive activation of NFκB and STAT3 in colorectal cancer cells[J]. Gastroenterology, 2014, 147(4): 847-859.
[6] IE SEGE C, NAGEL R, EGAN D A, et al. Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation[J]. EMBO J, 2007, 26(15): 3699-3708.
[7] ZHANG C Z, ZHANG J X, ZHANG A L, et al. MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma[J]. Mol Cancer, 2010, 9:229.
[8] GAROFALO M, DI LEVA G, ROMANO G, et al. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation[J]. Cancer Cell, 2009, 16(6): 498-509.
[9] HUANG J J, YU J, LI J Y, et al. Circulating microRNA expression is associated with genetic subtype and survival of multiple myeloma[J]. Med Oncol, 2012, 29(4): 2402-2408.
[10] CHI J, BALLABIO E, CHEN X H, et al. MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival[J]. Biol Direct, 2011, 6: 23.
[11] REID G, KIRSCHNER M B, VAN ZANDWIJK N, et al. Circulating microRNAs: association with disease and potential use as biomarkers[J]. Crit Rev Oncol Hematol, 2011, 80(2): 193-208.
[12] 黄晓军,路瑾,侯健,等. 中国多发性骨髓瘤诊治指南(2015年修订)[J].中华内科杂志,2015,54(12):1066-1070. HUANG Xiaojun, LU Jin, HOU Jian, et al. Guidelines for diagnosis and treatment of multiple myeloma in China (revised in 2015)[J]. Chinese Journal of Internal Medicine, 2015, 54(12): 1066-1070.(in Chinese)
[13] GALARDI S, MERCATELLI N, FARACE M G, et al. NF-kB and c-Jun induce the expression of the oncogenic miR-221 and miR-222 in prostate carcinoma and glioblastoma cells[J]. Nucleic Acids Res, 2011, 39(9): 3892-3902.
[14] LOTTEMAN C D, KENT O A, MENDELL J T, et al. Functional integration of microRNAs into oncogenic and tumor suppressor pathways[J]. Cell Cycle, 2008, 7(16): 2493-2499.
[15] VISONE R, CROCE C M. MiRNAs and cancer[J]. Am J Pathol, 2009, 174(4): 1131-1138.
[16] SREDNI S T, BONALDO M F, COSTA F F, et al. Upregulation of miR-221 and miR-222 in atypical teratoid/rhabdoid tumors: potential therapeutic targets[J]. Childs Nerv Syst, 2010, 26(3): 279-283.
[17] LE SAGE C, NAGEL R, EGAN D A, et al. Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation[J]. EMBO J, 2007, 26(15): 3699-3708.
[18] FELICETTI F, ERRICO M C, BOTTERO L, et al. The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms[J]. Cancer Res, 2008, 68(8): 2745-2754.
[19] DI MATTINO M T, GULLÀ A, CANTAFIO M E, et al. In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma[J]. Oncotarget, 2013, 4(2): 242-255.
[20] LIONETTI M, BIASIOLO M, AGNELLI L, et al. Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma[J/OL]. Blood, 2009, 114(25): e20-e26.
[1] 蔡成,王建平,钟志凤,戴志慧,王庆华,董武真,施红旗,刘庆伟,杜金林. 缺氧诱导因子1α和CD133预测直肠癌患者新辅助放化疗疗效的临床研究[J]. 浙江大学学报（医学版）, 2017, 46(1): 36-43.
[2] 边薇 等. 临时血液透析对维持性腹膜透析患者生存预后的影响[J]. 浙江大学学报（医学版）, 2016, 45(2): 195-200.
[3] 徐芳英 等. 神经内分泌分化在胃腺癌进展及患者预后中的意义[J]. 浙江大学学报（医学版）, 2016, 45(1): 24-30.
[4] 杨婉花等. MicroRNA-150联合脉搏指示连续性心输出量检测指标判断脓毒症休克患者预后的临床价值[J]. 浙江大学学报（医学版）, 2015, 44(6): 659-664.
[5] 严慎强等. 既往抗血小板治疗对合并颅内微出血急性缺血性卒中患者静脉溶栓的安全性分析[J]. 浙江大学学报（医学版）, 2015, 44(6): 618-624.
[6] 王科等. 进展性脑挫裂伤危险因素及与预后关系的分析[J]. 浙江大学学报（医学版）, 2015, 44(4): 410-416.
[7] 闫伟等. 经翼点小骨窗入路治疗前循环颅内动脉瘤患者临床疗效分析[J]. 浙江大学学报（医学版）, 2015, 44(4): 366-370.
[8] 席晓平, 曾令霞, 余方方, 刘华胜. DNMT3A基因突变对急性髓系白血病预后影响的meta分析[J]. 浙江大学学报（医学版）, 2015, 44(2): 197-203.
[9] 严晓波, 张圣, 严慎强, 楼敏. 不同严重程度急性缺血性卒中患者静脉溶栓预后的影响因素分析[J]. 浙江大学学报（医学版）, 2015, 44(1): 54-60.
[10] 刘建华，等. 瞬时弹性成像预测肝移植受者近期预后[J]. 浙江大学学报（医学版）, 2014, 43(6): 678-682.
[11] 张晓勤，蒲虹，王艺萍，等. 血浆凝溶胶蛋白水平在危重症患者预后评估中的应用[J]. 浙江大学学报（医学版）, 2014, 43(5): 541-.
[12] 苗华，等. 联合应用基因表达谱和拷贝数变异信息探索结直肠癌分子亚型[J]. 浙江大学学报（医学版）, 2014, 43(4): 420-426.
[13] 金淑清，等. 组织PBX2/ELF2表达水平与非小细胞肺癌患者预后相关性分析[J]. 浙江大学学报（医学版）, 2014, 43(4): 413-419.
[14] 曹培龙，等. 转录因子FOXC1、基质金属蛋白酶7在不同乳腺癌分子亚型中的表达及与临床病理的相关性分析[J]. 浙江大学学报（医学版）, 2014, 43(4): 406-412.
[15] 顾靖华， 邱宜军，陆亿华，徐旭东，徐志豪. 生活质量评估对慢性阻塞性肺疾病临床预后的价值[J]. 浙江大学学报（医学版）, 2014, 43(2): 207-211.